Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price…

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market

IndustryGrowthInsights, 09-07-2020: The research report on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://industrygrowthinsights.com/request-sample/?reportId=168493

The Major Manufacturers Covered in this Report:JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecScreenCellSilicon BiosystemsCirculating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs

The Research Study Focuses on:

By Types:CellSearchOthersCirculating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs

By Applications:Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

By Regions:

To get this report at incredible Discounts, visit @ https://industrygrowthinsights.com/ask-for-discount/?reportId=168493

The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report Consists of the Following Points:

Make an Inquiry of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=168493

In conclusion, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About IndustryGrowthInsights:IndustryGrowthInsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: sales@industrygrowthinsights.comWebsite: https://industrygrowthinsights.com

Read more:

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price...

Read more
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy – StreetInsider.com

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Continue reading here:

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy - StreetInsider.com

Read more
Fasting is not starvation or a fad, it is a discipline: Luke Coutinho – The Indian Express

Written by Jayashree Narayanan | Pune | Updated: July 9, 2020 6:38:55 pm Lifestyle coach Luke Coutinho on dry fasting and why it matters for your body. (Source: PR Handout)

Dry fasting for good health has raised eyebrows for its complete abstinence from food and water for an extended period, but the trend has been presented as a superior form of fasting and cleansing by Luke Coutinho in his book The Dry Fasting Miracle: From Deprive to Thrive, published by Penguin Random House India.

Coutinho, a holistic lifestyle coach-integrative medicine, who has co-authored the book with Sheikh Abdul Aziz Nuaimi aka Green Sheikh, from UAEs Ajman royal family, advocates dry fasting and intermittent fasting for healthy living. He talks to indianexpress.com on the book, why fasting is for everyone, and how it could be a way to build immunity given the pandemic concerns.

Excerpts:

Why do you think fasting is important?

Fasting in earlier times was built into ones lifestyle; people ate early because there was hardly any light after sunset and their next meal would only be after sunrise. This practice spread to all religions as a discipline due to its health and spiritual benefits. Sickness too was followed by fasting, because it allowed the body to redirect its energy towards healing and repairing. So, fasting is very natural to us, however, we have moved too far away from this concept because of the habit of constant nibbling, an abundance of food and storage options, etc. Our bodies were never designed to eat the amount of food we actually eat today. Overeating turns out to be one of the most common causes of sickness, more so when the quality of food is bad and inappropriate.

Today, science is proving how necessary fasting is for the immune system, digestive system, energy, spirituality, cardiovascular health, obesity, mental health and so much more.

Fasting draws up an image of no food, no water, and basically starving. How is dry fasting different?

Fasting is not starvation. Fasting is not deprivation. Fasting is a discipline where one willingly gives their body and digestive system a break, redirecting the energy towards rejuvenation and detoxification. Fasting is way more disciplined and planned. Skipping meals is not fasting.

Fasting must be practiced around the same time, so our body builds a memory around when it can expect food. Starvation can lead to nutritional deficiencies and acidity, whereas a well-planned fasting schedule eradicates acidity.

Isnt it dangerous for the body to go without food and, more importantly, water for more than 12 hours?

Dry fasting is a cleansing practice that involves complete abstinence from food and water (in any form) for a brief period of time, which could range from 10 hours to 16, 18, 20 hours, depending upon an individuals comfort level.

Our digestive system utilises almost 80 per cent of the energy into digestion, absorption and assimilation with 20 per cent of the energy towards healing, repair, recovery, growth, rejuvenation, detoxification and building the immune system. Too much eating, eating at the wrong timings, overeating can all drain energy, leaving little or no energy for repair and recovery. Fasting gives the digestive system a temporary shutdown, boosting the immune system, stem cell regeneration, hormonal balance, etc.

Dry fasting also sends our body into the autophagy mode (prolonged fasting) wherein its intelligence sacrifices the sickest cells and activates stem cell regeneration. All of this and more can be achieved through fasting, provided its done the right way.

Of course, if someone has a medical condition and cannot fast, they must refrain or modify it according to what their health experts recommend. For example, dry fasting may not suit someone with recurrent UTI infection, so he/she may adopt intermittent fasting. Or someone on water restriction may not be able to do intermittent fasting and can take short fasts under expert guidance only.

Interestingly, the book also mentions hard dry fasting, which means absolutely no contact with water, not just consumption of it but also bathing, washing or cleaning. Is it possible?

Yes, for a brief period of time. Also, hard dry fasting is intense, so its a personal choice whether one is comfortable with fasting by not washing hands, bathing, brushing, or handling water. Not many people are because they go to offices and travel or work and that is absolutely fine. Soft dry fasting (which includes brushing, bathing, etc) if done the right way is powerful in itself.

Fasting is viewed from a religious angle. But in the book, you mention, it is more than that. Can you elaborate?

Fasting does have religious and spiritual significance but its benefits extend beyond that. In fact, it improves the health of an individual from all dimensions physical, mental, emotional, intellectual as well as spiritual.

Fasting is also turning into another fad simply because it is used as a quick fix to achieve health goals, especially losing weight and belly fat.

Fasting is not a solution for weight gain. Use it to instill discipline with reference to eating and constant nibbling, start listening to your body.

Secondly, individuals try to complete with each other on fasting and the number of hours fasted. If someone is doing a 16-hour fast, everyone wants to do a 16 hour fast. Fasting is not a competition. Its what suits you. There is no magic number of hours one should fast.

Lastly, some people claim to be fasting but still have tea/coffee/juices, etc. Such an approach can be detrimental to ones health. Fasting is not a fad.

You mention that the human body is designed for fasting and the simplest way to begin is to have an early dinner. But, people rarely follow that and tend to even eat at odd hours. Is it healthy?

Times may have changed, but not the way the human body functions.While the wisdom of early dinner comes through our grandparents, today, science is proving how late-night meals mess up our digestion, immunity, blood sugar levels, weight, etc. The very fact that the pancreatic cells have melatonin receptors on them proves that our pancreas is meant to shut down when our body starts to secrete melatonin which is when the sun sets. A person who has had a late-night dinner would be able to answer how heavy and uncomfortable it could make one feel the next day and even during the course of the night. Even worse, if the dinner is heavy, because our body is just not designed to digest it at night.

By far, eating an early dinner which is as close to sunset is a powerful lifestyle change. It can result in better immunity, digestion, energy levels, better skin and hair, etc.

Considering each and everyones body systems are different, do you think dry fasting is everyone?

Absolutely. What do you lose by trying? Most people do not fear fasting, they resist moving out of their comfort zones. There are so many people who report literally magical benefits from fasting. If someone is in a dilemma, read about these inspiring stories.At the same time, fasting doesnt have to suit all. Also, if one form of fasting doesnt suit a person, for e.g. dry fasting, in case of a health condition like recurrent UTI, they can adopt intermittent fasting. In the end, its about what suits a person.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Books And Literature News, download Indian Express App.

IE Online Media Services Pvt Ltd

Originally posted here:

Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express

Read more
FDA Approves Talaris Therapeutics’ IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma -…

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Read more from the original source:

FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma -...

Read more
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration – BioSpace

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the companys principal contract development and manufacturing partners, today announced that they have extended their collaboration initiated in April 2018 for a period of five years through June 2025.

With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies in the upcoming years, including OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott Aldrich syndrome (WAS), as well as for additional pipeline programs including OTL-203 for mucopolysaccharidosis type I (MPS-I). MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

We are looking forward to continuing to build and expand upon our partnership with MolMed, who have supported the progression of many of our programs since their earliest clinical development stages, said Frank Thomas, president and chief operating officer of Orchard. Their expertise in gene therapy manufacturing, coupled with their deep knowledge of our programs, will be invaluable as our therapies for MLD and WAS approach anticipated approval and commercialization in Europe and across the globe.

Luca Alberici, MolMed's chief business officer, added, "We are pleased to have strengthened our collaboration with Orchard to support them in their mission of bringing potentially transformative therapies to those suffering from severe rare diseases. After being Orchards exclusive manufacturer for Strimvelis, we are looking forward to supporting their manufacturing needs for additional programs both in clinical trials and in potential commercial applications following the anticipated approval of OTL-200 for MLD in Europe later this year.

OTL-200 for MLD is currently under review by the EMA with a decision expected later this year.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

About MolMedMolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of novel cell and gene therapies. MolMed, established in 1996, has been listed since March 2008 on the Italian Stock Exchange managed by Borsa Italiana, and has its registered office in Milan, at the Biotechnology Department of Ospedale San Raffaele and an operating site at Bresso, at the OpenZone campus.

Availability of Other Information About OrchardInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for or marketing approval of its product candidates, and Orchards expectations concerning its partnership with MolMed. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the risk of delays in Orchards ability to commercialize its product candidates, if approved; and the risk that Orchard may not receive the expected benefits from its collaboration with MolMed or that Orchard or MolMed will not fully perform under the terms of their collaboration agreement. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter ended March 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC) on May 7, 2020, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Orchard Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

MolMed Contacts

Investor Relations & Communications DepartmentMolMed S.p.A.+39 02 21277.205investor.relations@molmed.com

Tommasina CazzatoPress OfficeCommunity Group+39 345 7357751tommasina.cazzato@communitygroup.it

More:

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration - BioSpace

Read more
Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain – Science Magazine

Plasma transfers exercise benefit in mice

Exercise has a broad range of beneficial healthful effects. Horowitz et al. tested whether the beneficial effects of exercise on neurogenesis in the brain and improved cognition in aged mice could be transferred in plasma (blood without its cellular components) from one mouse to another (see the Perspective by Ansere and Freeman). Indeed, aged mice that received plasma from young or old mice that had exercised showed beneficial effects in their brains without hitting the treadmill. The authors identified glycosylphosphatidylinositol-specific phospholipase D1 as a factor in plasma that might, in part, mediate this favorable effect.

Science, this issue p. 167; see also p. 144

Reversing brain aging may be possible through systemic interventions such as exercise. We found that administration of circulating blood factors in plasma from exercised aged mice transferred the effects of exercise on adult neurogenesis and cognition to sedentary aged mice. Plasma concentrations of glycosylphosphatidylinositol (GPI)specific phospholipase D1 (Gpld1), a GPI-degrading enzyme derived from liver, were found to increase after exercise and to correlate with improved cognitive function in aged mice, and concentrations of Gpld1 in blood were increased in active, healthy elderly humans. Increasing systemic concentrations of Gpld1 in aged mice ameliorated age-related regenerative and cognitive impairments by altering signaling cascades downstream of GPI-anchored substrate cleavage. We thus identify a liver-to-brain axis by which blood factors can transfer the benefits of exercise in old age.

The rest is here:

Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine

Read more
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+…

BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center.

In this trial, the Company utilizes its non-viral Sleeping Beauty genetic engineering technology to infuse CAR-T the day after electroporation. Ziopharms RPM CD19-specific CAR-T therapy results from the stable, non-viral insertion of DNA into the genome of resting T cells to co-express the chimeric antigen receptor (CAR), membrane-bound IL-15 (mbIL15) and a safety switch.

We are pleased to expand the scope of our clinical development with MD Anderson, as we seek to evaluate our RPM technology using CD19-specific CAR-T cells, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. RPM is a promising manufacturing solution, as T cells from the bloodstream are genetically reprogramed with DNA plasmids from the Sleeping Beauty system and then simply administered the next day.

Our CAR-T therapy can be administered at low cell doses, which may control cytokine release syndrome and is appealing for the treatment of patients including those with CD19-expressing malignancies that have relapsed after allogeneic bone marrow transplantation (BMT). There are limited effective treatment options for such patients as evidenced by the low rate of remission and poor long-term survival, Dr. Cooper added.

Up to 24 patients with advanced CD19+ leukemias and lymphomas who have relapsed after allogeneic BMT will be enrolled in this investigator-initiated trial (NCT03579888). The primary endpoint of the study is to determine the safety and maximum tolerated dose of donor-derived genetically modified CD19-specific T cells manufactured using the RPM process. An additional study is planned through Ziopharms joint venture with Eden BioCell to evaluate the RPM technology using patient-derived (autologous) CD19-specific CAR-T in Greater China.

Research reveals three-year survival for adults with CD19+ acute lymphoblastic leukemia after allogeneic BMT ranges from 30% to 65%.1 For patients with other CD19+ cancers, allogeneic BMT can provide three-year survival rates between 30% to 75%.1 Few patients experience a durable remission following allogeneic BMT, regardless of the treatment modality, with some having a median survival of only 2 to 3 months.2

About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit http://www.ziopharm.com.

Forward-Looking Statements DisclaimerThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, design and timing of the Company's research and development programs, the potential benefits of the Companys therapies, and the Companys expectations regarding the number of patients in its clinical trials. Although Ziopharms management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharms product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharms intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharms Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Investor Relations Contacts:Ziopharm Oncology:Chris TaylorVP, Investor Relations and Corporate CommunicationsT: 617.502.1881E: ctaylor@ziopharm.com

LifeSci Advisors:Mike MoyerManaging DirectorT: 617.308.4306E: mmoyer@lifesciadvisors.com

Media Relations Contact:LifeSci Communications:Patrick BurseyT: 646.876.4932E: pbursey@lifescicomms.com

1 D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2018. Available at https://www.cibmtr.org

2 Keil F, Prinz E, Kalhs P, et al. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia 2001; 15:355-361.

See more here:

Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+...

Read more
Benefits of Ashwagandha tea and how to make it – TheHealthSite

A strong immune system is the best weapon to fight the deadly COVID-19 disease. To keep your immunity at its best, it is essential to follow a healthy diet and regular exercise. Some spices and herbs are being widely promoted as having immunity-boosting properties amidst the pandemic. Ashwagandha is one such herb highly recommended by Ayurveda experts. Also Read - Ashwagandha for diabetes: How does it help in managing blood sugar?

For years, ashwagandha has been used in Ayurvedic medicine for treatment for various health conditions ranging from seasonal flu to depression and infertility. The name ashwagandha is derived from two Sanskrit words: ashvameaning horse and gandha-meaning smell. It is believed that in ancient times people used to consume it to get horse-like strength and energy. The botanical name of the plant is Withania somnifera, but it is also popularly known as Indian ginseng, poison gooseberry, and winter cherry. This traditional medicinal herb is well-known for its immunity-boosting, anti-ageing and de-stressing properties. Also Read - Ashwagandha: An ayurvedic herb with science-backed health benefits

Ayurveda experts also claim that ashwagandha has antibacterial, anti-inflammatory and anti-carcinogenic properties. It is being recommended as an effective natural remedy to fight depression, anxiety and to boost fertility and brain function. To get these health benefits, one can consume the roots of ashwagandha in various forms. You can just swallow a spoonful of ashwagandha powder or drink as herbal tea to give your immune system a boost during COVID-19 pandemic. Also Read - 5 natural remedies for getting rid of lyme disease during summer

Not just during the pandemic, but you can drink ashwagandha tea throughout the year to get its benefits. Follow the steps to prepare the delicious herbal tea:

Ingredients: 1 cup of water, 1 teaspoon ashwagandha powder, half lemon, honey as per taste.

Method:

Experts recommend drinking ashwagandha tea after having junk food or an unhealthy meal as it can help reduce the toxin level and enhance the digestive process.

A study, published in the Indian Journal of Psychological Medicine, revealed that Ashwagandha tea helps promote relaxation.

A study published in Phytochemistry suggested that Ashwagandha tea may benefit people with diabetes as it was found to help increase glucose uptake and insulin sensitivity. Another study published in the Indian Journal of Experimental Biology found that ashwagandha can lower blood sugar levels as effectively as an oral hypoglycemic drug.

A study that appeared in the Indian Journal of Medical Research indicated that the herb may have the potential to treat rheumatoid arthritis.

A study published in the journal Phytomedicine showed that Ashwagandha can reduce anxiety levels.

A study published in the AAPS Journal suggested that withaferin A a crystalline steroidal compound found in ashwagandha leaves may have cancer-fighting properties. Another study published in PLoS One revealed that this compound can kill chemo-resistant cancer stem cells in mice.

A study published in Fertility and Sterility investigated the impact of ashwagandha on fertility and found that it helped increase sperm count and sperm quality.

Published : July 9, 2020 6:48 pm | Updated:July 10, 2020 9:04 am

Continued here:

Benefits of Ashwagandha tea and how to make it - TheHealthSite

Read more
Live Cell Imaging Market Poised for Steady Growth in the Future 2020-2024 – Jewish Life News

The Live Cell Imaging Market provides qualitative and quantitative research to provide a complete and comprehensive analysis of the Competition, Insights market for Live Cell Imaging Market. It is a detailed report that focuses on primary and secondary factors, market share, top divisions, and regional analysis. It is a series of empirical analysis based on past data, current and future estimates and predicted Live Cell Imaging Market developments.

This report encases exhaustive investigation on the market and are surveyed through volume and worth information approved on three methodologies including top organizations incomes. It finishes up with exact and genuine market estimations considering all the boundaries and market elements. Each essential and unequivocal detail for the turn of events and limitation of the market is referenced in fine focuses with arrangements and proposals that may influence the market in not so distant future. Division of the market are concentrated explicitly to give significant information for valuable market ventures.

Information about the size of the market (before the finish of the estimate year), organizations that are destined to raise their serious capacities, driving fragments, and difficulties influencing the development of the market are given in the report. Diverse land zones are profoundly examined and a serious situation has been introduced to help new participants, driving market players, and financial specialists to distinguish rising economies.

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3898158?utm_source=Nilesh-JLN

Live Cell Imaging Market competition by top Manufacturers: Becton, Dickinson and Company, Carl Zeiss AG, Danaher Corporation (Leica Microsystems), GE Healthcare (Subsidiary of General Electric Company), Molecular Devices, LLC.

Market Segment as follows:

By the product type, the market is primarily split into: Equipment, Consumable, Software.

Live Cell Imaging Market by Application Segments: Cell Biology, Stem Cells, Drug Discovery.

Segment by Regions: North America, Asia-Pacific, Europe, Central & South America, Middle East & Africa, Other Regions.

Detailed evaluation about the capacity, significant industry features, cost structure, Live Cell Imaging Market demand and supply, production rate, consumption, import/export, Live Cell Imaging Market share, CAGR, gross margin and much more are briefly examined in this report. Additionally, it offers brief appraisal related to the Live Cell Imaging Market dynamics as well as recent marketing trends, alongside major industry segments and sub-segments.

Thus, with the rising adoption of the Live Cell Imaging Market in the international sector, the industry for global Live Cell Imaging Market is expected to represent a predicted outlook during the forecast phase from 2020- 2024. Additionally, the report on the Live Cell Imaging Market delivers a systematic representation of the growth opportunities, Live Cell Imaging Market dynamics and the existing trends are anticipated to shape the growth of the Live Cell Imaging Market across the globe.

To conclude, the Live Cell Imaging Market report will provide the clients with a high-yielding market analysis assisting them to understand the market status and come up with new market avenues to capture hold of the market share.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3898158?utm_source=Nilesh-JLN

Table of Content: Part I Live Cell Imaging Industry Overview Chapter One Live Cell Imaging Industry OverviewChapter Two Live Cell Imaging Up and Down Stream Industry Analysis Part II Asia Live Cell Imaging Industry (The Report Company Including the Below Listed But Not All) Chapter Three Asia Live Cell Imaging Market AnalysisChapter Four 2015-2020 Asia Live Cell Imaging Productions Supply Sales Demand Market Status and ForecastChapter Five Asia Live Cell Imaging Key Manufacturers AnalysisChapter Six Asia Live Cell Imaging Industry Development Trend Part III North American Live Cell Imaging Industry (The Report Company Including the Below Listed But Not All) Chapter Seven North American Live Cell Imaging Market AnalysisChapter Eight 2015-2020 North American Live Cell Imaging Productions Supply Sales Demand Market Status and ForecastChapter Nine North American Live Cell Imaging Key Manufacturers AnalysisChapter Ten North American Live Cell Imaging Industry Development Trend Part IV Europe Live Cell Imaging Industry Analysis (The Report Company Including the Below Listed But Not All) Chapter Eleven Europe Live Cell Imaging Market AnalysisChapter Twelve 2015-2020 Europe Live Cell Imaging Productions Supply Sales Demand Market Status and ForecastChapter Thirteen Europe Live Cell Imaging Key Manufacturers AnalysisChapter Fourteen Europe Live Cell Imaging Industry Development Trend Part V Live Cell Imaging Marketing Channels and Investment Feasibility Chapter Fifteen Live Cell Imaging Marketing Channels Development Proposals AnalysisChapter Sixteen Development Environmental AnalysisChapter Seventeen Live Cell Imaging New Project Investment Feasibility Analysis Part VI Global Live Cell Imaging Industry Conclusions Chapter Eighteen 2015-2020 Global Live Cell Imaging Productions Supply Sales Demand Market Status and ForecastChapter Nineteen Global Live Cell Imaging Industry Development TrendChapter Twenty Global Live Cell Imaging Industry Research Conclusions

About us:Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:Mr. Abhishek Paliwal Big Market Research5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect: +1-971-202-1575Toll Free: +1-800-910-6452E-mail: [emailprotected]

Read more from the original source:

Live Cell Imaging Market Poised for Steady Growth in the Future 2020-2024 - Jewish Life News

Read more
Hematopoietic Stem Cells Transplantation Market to Eyewitness Massive Growth by 2028: Leading Key Players Kite Pharma, Thermo Fisher Scientific,…

JCMR recently Announced Hematopoietic Stem Cells Transplantationstudy with 200+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Global Hematopoietic Stem Cells Transplantation Market. Global Hematopoietic Stem Cells Transplantation Marketallows you to get different methods for maximizing your profit. The research study provides estimates for Hematopoietic Stem Cells TransplantationForecast till 2028*. Some of the Leading key Companys Covered for this Research are Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems ,

Our report will be revised to address COVID-19 effects on the Global Hematopoietic Stem Cells Transplantation Market.

Click to get Global Hematopoietic Stem Cells Transplantation MarketResearch Sample PDF Copy Here @:jcmarketresearch.com/report-details/71715/sample

Global Hematopoietic Stem Cells Transplantation Market for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customers understanding, needs and wants. Also, reveals how effectively a company can meet their requirements. The market research collects data about the customers, marketing strategy, competitors. The Hematopoietic Stem Cells TransplantationManufacturing industry is becoming increasingly dynamic and innovative, with a greater number of private players entering the industry.

Important Features that are under offering & key highlights of the report:

1) Who are the Leading Key Company in Global Hematopoietic Stem Cells Transplantation Data Surway Report?

Following are list of players that are currently profiled in the report Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems ,

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

2) What will the market size be in 2028 and what will the growth rate be?

In 2019, the Global Hematopoietic Stem Cells Transplantation Market size was xx million USD and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2019-2028.

3) What are the Market Applications & Types:

The study is segmented by following Product Type: Autologous Transplant, Allogenic Transplant ,

Major applications/end-users industry are: Leukemia, Lymphoproliferative Disorders, Solid Tumors, Non-Malignant Disorders and Others

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2019 currency rates.

To comprehend Global Hematopoietic Stem Cells Transplantation Marketdynamics in the world mainly, the worldwide Hematopoietic Stem Cells Transplantation Marketis analyzed across major regions. JCMR also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.

Europe: UK, France, Italy, Germany, Spain, and Russia.

Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Enquire for customization in Report @jcmarketresearch.com/report-details/71715/enquiry

Competitive Analysis:

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems , includes its basic information like legal name, website, headquarters, its market position, historical background and top 10 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch including SWOT analysis of each key players etc.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involve the industry experts from the Hematopoietic Stem Cells Transplantationindustry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Bio-Waste Containers in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology-oriented perspectives.

Buy Full Copy with Exclusive Discount on Global Hematopoietic Stem Cells Transplantation Market Surway@jcmarketresearch.com/report-details/71715/discount

In this study, the years considered to estimate the market size of Hematopoietic Stem Cells Transplantationare as follows:

History Year: 2013-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020to 2028

Key Stakeholders in Global Hematopoietic Stem Cells Transplantation Market:

Hematopoietic Stem Cells Transplantation Manufacturers

Hematopoietic Stem Cells Transplantation Distributors/Traders/Wholesalers

Hematopoietic Stem Cells Transplantation Subcomponent Manufacturers

Industry Association

Downstream Vendors

**Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Select licenseversion and Buy this updated Research Report Directly @jcmarketresearch.com/checkout/71715

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:

JCMARKETRESEARCH

Jay (Marketing Manager)

Phone: +1 (925) 478-7203

Email:[emailprotected]

Connect with us at

http://www.jcmarketresearch.com

Original post:

Hematopoietic Stem Cells Transplantation Market to Eyewitness Massive Growth by 2028: Leading Key Players Kite Pharma, Thermo Fisher Scientific,...

Read more